Anat Cohen-Dayag

Title: The Innovative Contributions of Anat Cohen-Dayag

Introduction

Anat Cohen-Dayag is a prominent inventor based in Rehovot, Israel. She has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of seven patents to her name, her work focuses on novel drug targets for immune and non-immune based therapeutics.

Latest Patents

One of her latest patents involves polypeptides and polynucleotides, which serve as drug targets for producing drugs and biologics. This invention relates to a novel target for the production of immune and non-immune based therapeutics and for disease diagnosis. More specifically, it provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32, or FXYD3 antigens. These antigens are predicted co-stimulatory family members that are differentially expressed in various cancers, including lung cancer, ovarian cancer, and colon cancer. The invention also outlines diagnostic and therapeutic usages, including the modulation of B7 costimulation and related therapies for treating autoimmunity. Furthermore, it highlights the discovery of extracellular domains of these antigens and their variants, which are suitable targets for immunotherapy, cancer therapy, and drug development.

Career Highlights

Anat Cohen-Dayag is currently associated with Compugen Ltd. Corporation, where she continues to advance her research and innovations. Her work has positioned her as a key figure in the biotechnology sector, contributing to the development of cutting-edge therapies.

Collaborations

Anat collaborates with notable colleagues, including Shira Walach and Amir Toporik, who contribute to her research endeavors and innovations.

Conclusion

Anat Cohen-Dayag's contributions to biotechnology and her innovative patents underscore her role as a leading inventor in the field. Her work not only advances scientific knowledge but also holds the potential for significant therapeutic applications.